dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Yamamoto, Nobuyuki |
dc.contributor.author | Morán, Teresa |
dc.contributor.author | Gregorc, Vanesa |
dc.contributor.author | Dowell, Jonathan |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Planchard, David |
dc.contributor.author | Hayashi, Hidetoshi |
dc.date.accessioned | 2021-10-28T09:28:37Z |
dc.date.available | 2021-10-28T09:28:37Z |
dc.date.issued | 2020-10 |
dc.identifier.citation | Yamamoto N, Hayashi H, Planchard D, Morán T, Gregorc V, Dowell J, et al. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. Invest New Drugs. 2020 Oct;38:1588–1597. |
dc.identifier.issn | 1573-0646 |
dc.identifier.uri | https://hdl.handle.net/11351/6478 |
dc.description | 5-fluorouracil; Càncer de pulmó de cèl·lules no petites; Supervivència lliure de progressió |
dc.description.sponsorship | This work was supported by Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. The funding sources played a role in the study design; collection, analysis, and interpretation of data; writing of the report; and in the decision to submit the article for publication. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Investigational New Drugs;38 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Quimioteràpia |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.title | A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10637-020-00930-5 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1007/s10637-020-00930-5 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Yamamoto N] Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama Prefecture 641- 8509, Japan. [Hayashi H] Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. [Planchard D] Department of Medical Oncology, Thoracic Group, Institut Gustave Roussy, 114 rue Édouard- Vaillant, Villejuif Cedex 94805, France. [Morán T] Medical Oncology, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. B-ARGO, Carretera de Canyet s/n, Badalona, Barcelona 08916, Spain. [Gregorc V] Department of Oncology, Division of Experimental Medicine, IRCCS Ospedale San Raffaele, Via Olgettina, 60, Milano 20132, Italy. [Dowell J] Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. [Cedres S] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32246224 |
dc.identifier.wos | 000523083000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |